X
Xizhi Wen
Researcher at Sun Yat-sen University
Publications - 5
Citations - 95
Xizhi Wen is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Pembrolizumab & Mucosal melanoma. The author has an hindex of 1, co-authored 5 publications receiving 41 citations.
Papers
More filters
Journal ArticleDOI
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).
Lu Si,Xiaoshi Zhang,Yongqian Shu,Hongming Pan,Di Wu,Jiwei Liu,Fang Lou,Lili Mao,Xuan Wang,Xizhi Wen,Yanhong Gu,Lingjun Zhu,Shijie Lan,Xin Cai,Scott J. Diede,Yu Zhou,Jun Ge,Jianfeng Li,Haiyan Wu,Jun Guo +19 more
TL;DR: Pembrolizumab was well tolerated and provided clinically meaningful antitumor activity as second-line therapy in Chinese patients with advanced melanoma and two deaths occurred that were unrelated to treatment.
Journal ArticleDOI
Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Jing Jing Zhao,Xizhi Wen,Ya Ding,Dan Dan Li,Baoyan Zhu,Jingjing Li,De-Sheng Weng,Xing Zhang,Xiaoshi Zhang +8 more
TL;DR: It is demonstrated that irAEs were associated with a better clinical outcome after treatment with PD-1 inhibitor therapy in Chinese patients with advanced melanoma.
Journal ArticleDOI
Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis
Jingjing Li,Jiu-Hong Wang,Dan Dan Li,Xizhi Wen,Ya Ding,Xing Liu,Hang Jiang,Fuxue Huang,Xiaoshi Zhang +8 more
TL;DR: In this paper, the clinical data of 90 Chinese patients with completely resected, stage III cutaneous or acral melanoma who received either adjuvant PD-1 inhibitor or high-dose interferon α-2b (HDI) were analyzed.
Journal ArticleDOI
Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study.
Xing Liu,Jingjing Li,Ya Ding,Dan Dan Li,Xizhi Wen,De-Sheng Weng,Jiu-Hong Wang,Hang Jiang,Xiaoshi Zhang +8 more
TL;DR: In this paper, the authors evaluated the safety and tolerability of BRAFi and BRAFi-based combination therapies [MEK inhibitors (MEKi) or anti-programmed death-1 (PD-1) antibody] in Chinese patients with BRAF V600E/K mutation-positive metastatic melanoma.
Journal ArticleDOI
KEYNOTE-151: A phase Ib study of second-line pembrolizumab (Pembro) for Chinese patients (pts) with advanced or metastatic melanoma
Lu Si,Xiao Shi Zhang,Y. Shu,Hongming Pan,Dan Wu,Jiwei Liu,Fang Lou,Xizhang Wang,Xizhi Wen,Yanhong Gu,L. Zhu,Shijie lan,Xin Cai,Ying Zhou,J. Ge,Jia Li,Hao Wu,Jing Guo +17 more